SCYNEXIS, Inc. (FRA:135A)

Market Cap	27.93M -35.0%
Revenue (ttm)	2.50M -65.8%
Net Income	-21.56M
EPS	-0.44
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	263
Open	0.6430
Previous Close	0.6810
Day's Range	0.6430 - 0.6430
52-Week Range	0.4775 - 1.0610
Beta	n/a
RSI	59.90
Earnings Date	Mar 12, 2026

About SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has lic...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 28
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 135A

Financial Performance

Financial numbers in USD